Rxivist logo

A compound that directly and selectively stalls PCSK9 translation

By Nathanael G. Lintner, Kim F. McClure, Donna Petersen, Allyn T. Londregan, David W. Piotrowski, Liuqing Wei, Jun Xiao, Michael Bolt, Paula M. Loria, Bruce Maguire, Kieran F. Geoghegan, Austin Huang, Tim Rolph, Spiros Liras, Jennifer A. Doudna, Robert G. Dullea, Jamie H.D. Cate

Posted 25 Oct 2016
bioRxiv DOI: 10.1101/083097 (published DOI: 10.1371/journal.pbio.2001882)

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) plays a key role in regulating the levels of plasma low density lipoprotein cholesterol (LDL-C). Here we demonstrate that the compound PF-06446846 inhibits translation of PCSK9 by inducing the ribosome to stall around codon 34, mediated by the sequence of the nascent chain within the exit tunnel. We further show that PF-06446846 reduces plasma PCSK9 and total cholesterol levels in rats following oral dosing. Using ribosome profiling, we demonstrate that PF-06446846 is highly selective for the inhibition of PCSK9 translation. The mechanism of action employed by PF-06446846 reveals a previously unexpected tunability of the human ribosome, which allows small molecules to specifically block translation of individual transcripts.

Download data

  • Downloaded 3,315 times
  • Download rankings, all-time:
    • Site-wide: 1,552 out of 89,671
    • In systems biology: 35 out of 2,313
  • Year to date:
    • Site-wide: 53,110 out of 89,671
  • Since beginning of last month:
    • Site-wide: 36,607 out of 89,671

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)